Contraindicated and off-label drug use in pediatric outpatients in the Nordic countries
Tuire Prami 1, Disa Långström 2, Ilona Iso-Mustajärvi 1, Niklas Sandler 2

1EPID Research, EPID Research, Espoo, Finland; 2Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku, Finland

RATIONALE
Real-life data on off-label use of drugs - contraindicated drug use in particular - are scarce. Only a few pharmacoepidemiological register studies have included nationwide data from several countries. Earlier we identified that the Nordic citizens form an outstandingly large homogenous population for outpatient studies also in children (1).

OBJECTIVES
The aim of the study was to evaluate the occurrence of off-label drug use, and utilization of medicines contraindicated for children, despite the restriction in the summary of products characteristics (SPCs) in Finland, Sweden, Norway and Denmark.

METHODS
Drugs with contraindications and potential off-label use, in terms of age and dose, for pediatric patients were searched in electronic SPCs. Finnish SPCs that mention any type of pediatric patients in the contraindications chapter were searched first, and the results were then reviewed in Swedish, Norwegian and Danish SPCs. The survey on off-label use focused on the 30 most commonly used drugs in children in Nordic countries (1).

Users of all contraindicated drugs and of the most commonly used off-label drugs were identified in national administrative prescription databases in the four Nordic countries run by The Social Insurance Institution of Finland, The National Board of Health and Welfare in Sweden, The Norwegian Institute of Public Health, and The National Institute for Health Data and Disease Control in Denmark. The searches were based on anatomical therapeutic chemical classification codes (ATCs).

No personal level data was requested for this study, thus no ethical approval was applied. EPID Research is a member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and all the work there is done following the ENCePP Code of Conduct.

RESULTS AND CONCLUSIONS
Of 49 contraindicated drugs found, the greatest proportional use was found for etoricoxib in Finland (N=1388; 2.5/10,000 <16-y./year), diclofenac in Sweden (N=1212; 1.4/10,000 <14-y./year), oxymetazoline in Norway (N=2160; 29/10,000 <2-y./year), and for zopiclone in Denmark (N=1586; 2.2/10,000 <18-y./year). The common utilization of these drugs stood up in these particular countries only. For oxymetazoline this may be due to strict age limit especially in Norway; for zopiclone there was an age limit only in Denmark. The same does not explain the wider contraindicated use of etoricoxib in Finland or diclofenac in Sweden. There were no remarkable changes between the study years in relation to contraindicated drug use, which was the case in off-label used drugs. The most commonly used off-label drugs in each country by years are shown in Figure 1.

ACKNOWLEDGEMENTS
• The study was part of master’s thesis work of Disa Långström, and it was financially supported by EPID Research.
• We thank personnel of the original register holders about personal communication. (Case number 29134/2015 in Sweden and 15/2914/EPLI/SITO in Norway.)
• Rosa Juuti, MSc from EPID Research is acknowledged for presenting the poster in ICPE 2016.

REFERENCES